AI is about to change healthcare. These 7 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
To own Kajima, you need to be comfortable with a construction-led earnings story backed by disciplined capital allocation rather than a high and steadily rising dividend. The new FY2027 guidance, with revenues of ¥2,900 billion and EPS of ¥368.20, keeps the profit narrative intact, but the cut in the full-year dividend to ¥73.00 per share underlines that management is willing to rebalance cash returns when conditions warrant. The higher interim dividend and continued buybacks, alongside the small share cancellation and stock remuneration moves, suggest a tilt toward more flexible shareholder returns. The recent ¥40.00 billion in unsecured bonds lengthens funding and supports future projects, but it adds leverage at a time when the share price has already pulled back sharply, keeping execution risk and cash flow coverage squarely in focus.
However, there is one cash flow concern here that investors should not ignore. Despite retreating, Kajima's shares might still be trading above their fair value and there could be some more downside. Discover how much.Explore 2 other fair value estimates on Kajima - why the stock might be worth over 3x more than the current price!
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
Every day counts. These free picks are already gaining attention. See them before the crowd does:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com